Mechanistic modeling-guided optimization of microneedle-based skin patch for rapid transdermal delivery of naloxone for opioid overdose treatment

Akeemat Tijani,Prashant Dogra,Maria J. Peláez,Zhihui Wang,Vittorio Cristini,Ashana Puri
DOI: https://doi.org/10.1007/s13346-022-01202-w
2022-07-27
Drug Delivery and Translational Research
Abstract:Naloxone, an FDA-approved opioid inhibitor, used to reverse opioid overdose complications has up till date faced challenges associated with its delivery. Limitations include the use of invasive delivery forms and the need for frequent redosing due to its short half-life. The goal of the current study was to design a transdermal rapidly dissolving polymeric microneedle (MN) patch with delivery and pharmacokinetic properties comparable to that seen with the commercially available NAL products, eliminating their delivery limitations. Patches of varying dimensions (500 μm; 100 array,800 μm; 100array, and 600 μm; 225 array) were fabricated to evaluate the effect of increasing MN length, and density (no. of needles/unit area) on drug release. Drug dose in each of these patches was 17.89 ± 0.23 mg, 17.2 ± 0.77 mg, and 17.8 ± 1.01 mg, respectively. Furthermore, the insertion efficiency of each of the MN patches was 94 ± 4.8%, 90.6 ± 1.69%, and 96 ± 1.29%, respectively. Compared to passive permeation, a reduced lag time of about 5–15 min was observed with a significant drug flux of 15.09 ± 7.68 g /cm 2 /h seen in the first 1 h ( p < 0.05) with the array of 100 needles (500 μm long). Over 24 h, a four and ten-fold increase in permeation was seen with the longer length and larger density MN patch, respectively, when compared to the 500 μm (100 array) patch. Model simulations and analyses revealed the significance of needle base diameter and needle count in improving systemic pharmacokinetics of NAL.
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?